In February 2024, it was announced that Takeda Pharma would partner with Biological E to make 50 million dengue vaccines.
Representative image
The World Health Organisation on Wednesday, 15 May, announced that it had prequalified a new vaccine for dengue, making TAK-003 the second dengue vaccine to be prequalified by it. Developed by Japanese multinational pharmaceutical company Takeda, it is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue.